Market Overview

UPDATE: Canaccord Genuity Initiates Synageva BioPharma at Buy, $60 PT; Attractive Orphan Platform

Related GEVA
Ultragenyx Downgraded At Morgan Stanley, Valuation 'Stretched' And Pipeline Faces Execution Risk
JMP Starts Ultragenyx At Outperform, Pipeline Maturity Expected To Continue

Canaccord Genuity initiates its coverage on Synageva BioPharma (NASDAQ: GEVA) with a Buy rating and a price target of $90.

Canaccord Genuity says, "Early but encouraging SBC--102 proof --102 proof--of --of- ofof-concept data: --concept data: The lateonset LAL-D Phase 1/2 trial data presented to date has been impressive – rapid and significant decreases in hepatic enzymes indicate that SBC-102 is having the predicted biochemical role in combating liver abnormalities."

GEVA closed at $38.50 on Friday.

Latest Ratings for GEVA

May 2015BairdDowngradesOutperformNeutral
Mar 2015JP MorganDowngradesOverweightNeutral
Feb 2015CitigroupMaintainsNeutral

View More Analyst Ratings for GEVA
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Initiation Pre-Market Outlook Analyst Ratings


Related Articles (GEVA)

View Comments and Join the Discussion!

Get Benzinga's Newsletters